02.03.2023 - MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) - Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments .
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Malignant melanoma patients treated with immunotherapy combination UV1 and pembrolizumab in phase I clinical trialConsistently high overall survival (OS).
Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.